Argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer.
Fair value: 177.50€
Premium: 16%
Average yearly return: +55%
Buy cheap around: +172.50€
On June the 1rst ARGX announced the closing of its previously announced global offering of an aggregate of 4,207,292 ordinary shares . The gross proceeds from the global offering were approximately $862.5 million (approximately €784.7 million).
